


CLAIMS

1. A piperidine derivative of the Formula I:




or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, wherein

R¹ represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl;

R³ represents -C(=O)-O-R^c or -CH₂-O-R^c;
wherein R^c represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkylalkyl;

R⁴ represents



wherein R^a and R^b independently of each other represents halo or trifluoromethyl with the proviso that the mixture of isomers is not (±)-cis/trans-1-methyl-3-methoxycarbonyl-4-(3,4-dichlorophenyl)-piperidine or (±)-cis/trans-1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine.

2. The chemical compound of claim 1, wherein R¹ represents hydrogen or alkyl.

3. The chemical compound of either of claims 1-2, wherein R^a and R^b independently of each other represent halo.

4. The chemical compound of any one of claims 1-3, wherein R³ represents -C(=O)-O-R^c.

5. The chemical compound of any one of claims 1-3, wherein R³ represents -CH₂-O-R^c.

6. The chemical compound of any one of claims 1-5, wherein R^c represents hydrogen, alkyl or cycloalkylalkyl.
7. The chemical compound of claim 1, wherein
5 R^1 represents hydrogen or alkyl;
 R^c represents hydrogen, alkyl or cycloalkylalkyl; and
 R^a and R^b independently of each other represent halo.
8. The chemical compound of claim 1, wherein
10 R^1 represents hydrogen or alkyl;
 R^3 represents $-\text{CH}_2-\text{O}-R^c$;
 R^c represents alkyl or cycloalkylalkyl; and
 R^a and R^b independently of each other represent halo.
- 15 9. The chemical compound of claim 1, which is
1-methyl-4-(3,4-dichlorophenyl)-piperidine-3-carboxylic acid methyl ester;
1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine;
1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
1-methyl-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
20 1-methyl-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
1-methyl-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
25 or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
10. The chemical compound of claim 1, which is
(\pm)-Cis-1-methyl-4-(3,4-dichlorophenyl)-piperidine-3-carboxylic acid methyl ester;
30 (\pm)-Trans-1-methyl-4-(3,4-dichlorophenyl)-piperidine-3-carboxylic acid methyl ester;
(\pm)-Cis-1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(\pm)-Trans-1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Cis-1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine;
35 (-)-Cis-1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Trans-1-methyl-3-hydroxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(\pm)-Cis-1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(\pm)-Cis-1-methyl-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;

- (±)-Trans-1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(±)-Trans-1-methyl-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Cis-1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Cis-1-methyl-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
5 (-)-Cis-1-methyl-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Cis-1-methyl-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Cis-1-methyl-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Cis-1-methyl-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
10 (-)-Trans-1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-1-methyl-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Trans-1-methyl-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Trans-1-methyl-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Trans-1-methyl-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
15 (+)-Cis-1-methyl-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-1-methyl-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-1-methyl-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-
piperidine;
(-)-Cis-1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
20 (+)-Cis-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Cis-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Cis-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Cis-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Cis-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
25 (-)-Cis-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Trans-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Trans-3-methoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
30 (-)-Trans-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-3-cyclopropylmethoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Cis-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(-)-Cis-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
(+)-Trans-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
35 (-)-Trans-3-isobutoxymethyl-4-(3,4-dichlorophenyl)-piperidine;
or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of any one of claims 1-10, or any of its isomers or any mixture of its

isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

12. Use of the chemical compound of any of claims 1-10, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.
13. The use according to claim 12, for the manufacture of a pharmaceutical pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
14. The use according to claim 12, wherein the disease, disorder or condition is mood disorder, depression, atypical depression, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, social phobia, post-traumatic stress disorder, acute stress disorder, drug addiction, drug misuse, cocaine abuse, nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, post-operative pain, post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-maintained pain, trigeminal neuralgia, dental pain, myofascial pain, phantom-limb pain, bulimia, premenstrual syndrome, late luteal phase syndrome, post-traumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence, nocturnal incontinence, premature ejaculation, erectile difficulty, anorexia nervosa, sleep disorders, autism, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage, or Gilles de la Tourettes disease.

15. A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-10, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.